A potent agonist of D2 receptors
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

B-HT 920 (hydrochloride)

Item No. 14177

Technical Information
Formal Name
5,6,7,8-tetrahydro-6-(2-propen-1-yl)-4H-thiazolo[4,5-d]azepin-2-amine, dihydrochloride
CAS Number
36085-73-1
Molecular Formula
C10H15N3S • 2HCl
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
PBS (pH 7.2): 10 mg/ml
λmax
225, 263 nm
SMILES
NC(S1)=NC2=C1CCN(CC=C)CC2.Cl.Cl
InChi Code
InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H
InChi Key
DPQAXNSOFFYKDS-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    B-HT 920 is a potent agonist of dopamine 2 (D2) receptors (Ki = 5.8 nM) that shows selectivity for D2 over D3 and D4 receptors.1,2,3 It has neuroprotective and regenerative effects in animal models of Parkinson’s disease.4 B-HT 920 is also an agonist of α2-adrenergic receptors and an antagonist of serotonin-3 (5-HT3; Ki = 0.35 µM) receptors.5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Maina, F.K., and Mathews, T.A. A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. ACS Chem Neurosci. 1(6), 450-462 (2010).

    2. Mewshaw, R.E., Kavanagh, J.J., Stack, G., et alNew generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. J. Med. Chem. 40(26), 4235-4256 (1997).

    3. Robertson, G.S., Tham, C.S., Wilson, C., et alIn vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J. Pharmacol. Exp. Ther. 264(3), 1344-1351 (1993).

    4. Kitamura, Y. Dopaminergic neuroprotection and reconstruction of neural network tiara. Yakugaku Zasshi 130(10), 1263-1272 (2010).

    5. Nishio, H., Kohno, Y., Fujii, A., et al5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole. Gen. Pharmcol. 27(5), 778-785 (1996).

    6. Rocco, D., and Taira, C.A. Adrenoceptor involvement in the cardiovascular responses to B-HT 920 in sinoaortic denervated rats. Gen. Pharmcol. 32(1), 29-34 (1999).